Results 261 to 270 of about 1,516,828 (318)

Epidemiological Features and Risk Factors of SARS-CoV-2 Reinfection: A Retrospective Cohort Analysis in Xiamen, China (Preprint)

Tianmu Chen, Yao Wang, Yidun Zhang, Zeyu Zhao, Buasiyamu Abudunaibi, Kang Fang, Huimin Qu, Qiao Liu, Yanhua Su, Chenghao Su, Zhinan Guo, Zhinan Guo   +11 more
openalex   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Variant-Specific Kinetics of SARS-CoV-2 Anti-Nucleocapsid Antibodies and Household Transmission in Families During Anchestral, Alpha, Delta and Omicron Periods. [PDF]

Life (Basel)
Filippatos F, Tatsi EB, Syriopoulou V, Michos A.   +3 more
europepmc   +1 more source

Genomic validation of IRF3 antagonism by ORF4a, ORF4b, ORF5, and M in 272 human MERS-CoV isolates

Bhatti, Tahir
openalex   +1 more source

Review of: "[Review Article] Interventional Radiology And CT Scan in SARS-COV-2: A Review" [PDF]

Rajashri Khanai
openalex   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report

British Journal of Clinical Pharmacology, EarlyView.
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart, Emiel Leegwater, Thomas H. Ottens, Emile F. Schippers, Erik B. Wilms, David M. Burger, Cees van Nieuwkoop, Liesbeth B. E. Bosma   +7 more
wiley   +1 more source

MERS-CoV and SARS-CoV-1 proteins inhibit the IFN-α JAK/STAT pathway of epithelial cells, via IFN-λ-induced USP18. [PDF]

Front Immunol
Zhang Y, Stevenson NJ.
europepmc   +1 more source

SARS-COV-2 CT

Hongyan Xu
openalex   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates. [PDF]

PLoS One
Nelson CE, Kauffman KD, Sakai S, Newbolt T, Buchanan J, Foreman TW, Walker AM, Gomez F, Fleegle JD, Tuberculosis Imaging Program, Herbert R, Hill T, Turan S, Mayer-Barber KD, Johnson RF, Via LE, Barber DL.   +16 more
europepmc   +1 more source